Advertisement

Topics

Mylan settles for overcharging in suit brought by EpiPen competitor

12:42 EDT 21 Aug 2017 | British Medical Journal

The drug company Mylan NV has agreed to pay $465m (£360m; €395m) to settle claims that it overcharged the US social healthcare program Medicaid for its anaphylaxis treatment EpiPen, a portable,...

Original Article: Mylan settles for overcharging in suit brought by EpiPen competitor

NEXT ARTICLE

More From BioPortfolio on "Mylan settles for overcharging in suit brought by EpiPen competitor"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...